Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GGT1 | P19440 | 1/20 | 0.45 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.44 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.44 |
| ▸ | ARG1 | P05089 | 2/20 | 0.41 |
| ▸ | ARG2 | P78540 | 2/20 | 0.41 |
| ▸ | NOS2 | P35228 | 4/20 | 0.41 |
| ▸ | NOS1 | P29475 | 2/20 | 0.41 |
| ▸ | BLM | P54132 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | FYN | P06241 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL160650 | 1.00 | GGT1 (0.45) | GGT1GRM2GRM3ARG1ARG2 | |
| SCHEMBL160649 | 1.00 | GGT1 (0.45) | GGT1GRM2GRM3ARG1ARG2 | |
| Hydrochloric Acid SCHEMBL8995745 | 0.98 | GGT1 (0.43) | GGT1GRM2GRM3ARG1ARG2 | |
| Hydrochloric Acid SCHEMBL8995749 | 0.98 | GGT1 (0.43) | GGT1GRM2GRM3ARG1ARG2 | |
| Hydrochloric Acid SCHEMBL1025465 | 0.98 | GGT1 (0.43) | GGT1GRM2GRM3ARG1ARG2 | |
| Hydrochloric Acid SCHEMBL5764217 | 0.98 | GGT1 (0.43) | GGT1GRM2GRM3ARG1ARG2 | |
| SCHEMBL2721337 | 0.83 | ARG1 (0.50) | GGT1GRM2GRM3ARG1ARG2 | |
| SCHEMBL497269 | 0.83 | GGT1 (0.43) | GGT1GRM2GRM3ARG1ARG2 | |
| SCHEMBL27601801 | 0.82 | SLC7A5 (0.40) | GGT1GRM2GRM3ARG1ARG2 | |
| SCHEMBL1300782 | 0.81 | GABRR1 (0.43) | GGT1GRM2GRM3ARG1ARG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1305 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260001928-A1 | CRF2 RECEPTOR AGONISTS AND THEIR USE IN THERAPY | CORTERIA PHARMACEUTICALS (FR) | 2026-01-01 | — | — | US | claimed |
| EP-4482578-B1 | CRF2 RECEPTOR AGONISTS AND THEIR USE IN THERAPY | CORTERIA PHARMACEUTICALS (FR) | 2025-12-24 | — | — | EP | claimed |
| EP-4568707-A1 | PEPTIDE-BASED DELIVERY AGENT AND METHOD OF MAKING AND USING THE SAME | EndoRel Biosciences LLC (US) | 2025-06-18 | — | — | EP | claimed |
| CN-120076830-A | Peptide-based delivery agents and methods of making and using the same | 恩多雷尔生物科学有限责任公司 | 2025-05-30 | — | — | CN | claimed |
| CN-119823223-A | Apelin peptide energy macrocycle and application thereof | SOCPRA健康与人文科学有限公司 | 2025-04-15 | — | — | CN | claimed |
| CN-119431514-A | Polypeptide derivative with triple targeting agonism of GCGR, GIPR and GLP-1R | 南京知和医药科技有限公司 | 2025-02-14 | — | — | CN | claimed |
| EP-4482578-A1 | CRF2 RECEPTOR AGONISTS AND THEIR USE IN THERAPY | Corteria Pharmaceuticals (FR) | 2025-01-01 | — | — | EP | claimed |
| CN-118843638-A | CRF2 receptor agonists and their use in therapy | 科尔特瑞制药公司 | 2024-10-25 | — | — | CN | claimed |
| EP-4448547-A1 | APELINERGIC MACROCYCLES AND USES THEREOF | Socpra Sciences Santé Et Humaines S.E.C. (CA) | 2024-10-23 | — | — | EP | claimed |
| CN-118829646-A | Apelin peptide energy macrocycle and application thereof | SOCPRA健康与人文科学有限公司 | 2024-10-22 | — | — | CN | claimed |
| WO-2007088099-A2 | COMPOUNDS FOR THE TREATMENT OF ISCHEMIA AND NEURODEGENERATION | ONCOREG AB (SE) | 2007-08-09 | — | — | WO | claimed |
| WO-2007080194-A2 | USE OF TPP II INHIBITORS IN COMBINATION WITH GAMMA-IRRADIATION FOR THE TREATMENT OF CANCER | ONCOREG AB (SE) | 2007-07-19 | — | — | WO | claimed |
| US-7132394-B2 | PTH-like peptides | ABIOGEN PHARMA S.P.A. (IT) | 2006-11-07 | — | — | US | claimed |
| US-20060019902-A1 | PTH-like peptides | ABIOGEN PHARMA S.P.A. (IT) | 2006-01-26 | — | — | US | claimed |
| EP-1619204-A1 | PTH-like peptides | Abiogen Pharma S.p.A. (IT) | 2006-01-25 | — | — | EP | claimed |
| CN-1578786-A | Linear basic compounds having NK-2 antagonistic activity and formulations thereof | MENARINI RICERCHE SPA (IT) | 2005-02-09 | — | — | CN | claimed |
| US-20040259930-A1 | Linear basic compounds having nk-2 antagonist activity and formulations thereof | MALESCI INSTITUTO FARMACOBIOLOGICO S.P.A. (IT) | 2004-12-23 | — | — | US | claimed |
| EP-1442050-A2 | LINEAR BASIC COMPOUNDS HAVING NK-2 ANTAGONIST ACTIVITY AND FORMULATIONS THEREOF | MALESCI ISTITUTO FARMACOBIOLOGICO S.p.A. (IT) | 2004-08-04 | — | — | EP | claimed |
| WO-2003037916-A2 | LINEAR BASIC COMPOUNDS HAVING NK-2 ANTAGONIST ACTIVITY AND FORMULATIONS THEREOF | MALESCI ISTITUTO FARMACOBIOLOGICO S.P.A. (IT) | 2003-05-08 | — | — | WO | claimed |
| WO-1988002756-A2 | PEPTIDE DERIVATIVES | SANDOZ AG (CH) | 1988-04-21 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259930-A1 | Linear basic compounds having nk-2 antagonist activity and formulations thereof | BDKRB2, BDKRB1, TACR2 | GGT1 4055/4885GRM2 907/4885GRM3 1374/4885 |
| US-20260001928-A1 | CRF2 RECEPTOR AGONISTS AND THEIR USE IN THERAPY | GIPR, NPY2R, NPY1R | GGT1 2692/4885GRM2 28/4885GRM3 41/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.